Answers are grounded in this paper and cite their sources.
The activity of MK-0826, a new carbapenem, against 309 Bacteroides fragilis group strains was investigated and compared with that of 11 other beta-lactam and 5 non-beta-lactam agents. MK-0826 showed excellent activity (MICs ranged from < or =0.06 to 4 microg/ml). The new carbapenem may be useful in the treatment of mixed anaerobic infections involving B. fragilis group strains.
No takes yet. Share an insight, caveat, or question.
Betriú et al. (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: